[go: up one dir, main page]

WO2007011411A3 - Fragment n du facteur oedematogene utilise comme antigene pour l'immunisation contre l'anthrax - Google Patents

Fragment n du facteur oedematogene utilise comme antigene pour l'immunisation contre l'anthrax Download PDF

Info

Publication number
WO2007011411A3
WO2007011411A3 PCT/US2005/039799 US2005039799W WO2007011411A3 WO 2007011411 A3 WO2007011411 A3 WO 2007011411A3 US 2005039799 W US2005039799 W US 2005039799W WO 2007011411 A3 WO2007011411 A3 WO 2007011411A3
Authority
WO
WIPO (PCT)
Prior art keywords
fragment
edema factor
antigen
immunization against
against anthrax
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/039799
Other languages
English (en)
Other versions
WO2007011411A2 (fr
Inventor
Michael E. Pichichero
Mingtao Zeng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
University of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Rochester filed Critical University of Rochester
Publication of WO2007011411A2 publication Critical patent/WO2007011411A2/fr
Anticipated expiration legal-status Critical
Publication of WO2007011411A3 publication Critical patent/WO2007011411A3/fr
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions et des procédés permettant d'obtenir un fragment non catalytique du facteur oedématogène de Bacillus anthracis. En particulier, l'invention porte sur un peptide ou un acide nucléique codant pour un peptide comprenant un fragment non catalytique du facteur oedématogène. L'invention se rapporte en outre à des procédés permettant d'utiliser ce fragment comme antigène de l'anthrax afin de déclencher une réponse immunitaire efficace pour traiter ou prévenir l'infection par l'anthrax.
PCT/US2005/039799 2004-11-05 2005-11-04 Fragment n du facteur oedematogene utilise comme antigene pour l'immunisation contre l'anthrax Ceased WO2007011411A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62538204P 2004-11-05 2004-11-05
US60/625,382 2004-11-05

Publications (2)

Publication Number Publication Date
WO2007011411A2 WO2007011411A2 (fr) 2007-01-25
WO2007011411A3 true WO2007011411A3 (fr) 2011-04-21

Family

ID=37669287

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/039799 Ceased WO2007011411A2 (fr) 2004-11-05 2005-11-04 Fragment n du facteur oedematogene utilise comme antigene pour l'immunisation contre l'anthrax

Country Status (1)

Country Link
WO (1) WO2007011411A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009063507A1 (fr) * 2007-11-12 2009-05-22 Rakesh Bhatnagar Vaccin d'adn contre le charbon

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329156B1 (en) * 1999-03-22 2001-12-11 The Regents Of The University Of California Method for screening inhibitors of the toxicity of Bacillus anthracis

Also Published As

Publication number Publication date
WO2007011411A2 (fr) 2007-01-25

Similar Documents

Publication Publication Date Title
WO2003080114A3 (fr) Adjuvant pour vaccins
WO2006068663A3 (fr) Compositions de vaccin et procedes permettant de traiter des infections par coronavirus
WO2004075829A3 (fr) Vaccin contre la grippe contenant un adjuvant
WO2003101397A3 (fr) Vaccins tetravalents contre la dengue
WO2008060510A3 (fr) Procédés et composition pour la modification du locus du récepteur humain des glucocorticoïdes
EP4219566A3 (fr) Antigènes du vrs recombinants
WO2003063766A3 (fr) Nouvelle compositions immunogenes utilisees pour la prevention et le traitement de la meningococcie
WO2007024705A3 (fr) Procede de traitement de la depression au moyen d'un anticorps anti-tnf-alpha
WO2007120673A3 (fr) Peptides wt1 immunogènes et leurs méthodes d'utilisation
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
WO2006034292A3 (fr) Anticorps dirige contre le virus respiratoire syncytial et procedes de production de vaccins associes
WO2005013918A3 (fr) Compositions, methodes et kits de vaccins a base de sous-unite de poxvirus
WO2007030810A3 (fr) Moniteur de sang total multiparametrique et procede associe
WO2009154995A3 (fr) Anticorps du récepteur de l'interleukine 10 (il-10r) et méthodes d'utilisation
WO2005120565A8 (fr) Vaccins contre le sras et procedes de production d'anticorps tres puissants
WO2005120567A3 (fr) Anticorps monoclonaux de neutralisation de toxine d'anthrax humain et procedes d'utilisation
WO2004045529A3 (fr) Vaccin contre le virus du nil occidental
PT1409692E (pt) Novos péptidos do derivados da proteína g do vírus respiratório sincicial (vrs) e sua utilização numa vacina
WO2007021672A3 (fr) Vaccination contre l'infection par le virus de la dengue
WO2009085025A3 (fr) Vaccin
WO2008048344A3 (fr) Antigènes de bacillus anthracis, compositions pour vaccins et procédés connexes
WO2006042149A3 (fr) Determination et reduction de l'immunoresistance a la therapie de la toxine botulinique a l'aide de peptides de la toxine botulinique de type a
WO2004031210A3 (fr) Constructions optimisees a plusieurs epitopes et utilisations de ces dernieres
WO2008080091A3 (fr) Activation du chemin rig-i
WO2009117373A3 (fr) Traitement et prévention des infections à gardnerella vaginalis

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05858472

Country of ref document: EP

Kind code of ref document: A2